acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
Company profile
Ticker
ACST
Exchange
Website
CEO
Janelle D'Alvise
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acasti Innovation AG ...
ACST stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
1 Apr 24
8-K
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12 Feb 24
10-Q
2024 Q3
Quarterly report
12 Feb 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
8-K
Changes in Registrant's Certifying Accountant
15 Dec 23
10-Q
2024 Q2
Quarterly report
13 Nov 23
8-K
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
13 Nov 23
8-K
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
23 Oct 23
EFFECT
Notice of effectiveness
17 Oct 23
424B3
Prospectus supplement
16 Oct 23
Transcripts
ACST
Earnings call transcript
2023 Q3
14 Feb 23
ACST
Earnings call transcript
2023 Q3
14 Feb 23
ACST
Earnings call transcript
2023 Q2
15 Nov 22
ACST
Earnings call transcript
2023 Q2
14 Nov 22
ACST
Earnings call transcript
2023 Q1
11 Aug 22
ACST
Earnings call transcript
2023 Q1
11 Aug 22
ACST
Earnings call transcript
2022 Q4
21 Jun 22
ACST
Earnings call transcript
2022 Q4
21 Jun 22
ACST
Earnings call transcript
2021 Q3
14 Feb 22
ACST
Earnings call transcript
2022 Q3
14 Feb 22
Latest ownership filings
4/A
Carrie D'Andrea
10 May 24
4/A
Amresh Kumar
10 May 24
4
Carrie D'Andrea
8 May 24
4
Amresh Kumar
8 May 24
4
R. Loch Macdonald
8 May 24
4
Robert J DelAversano
8 May 24
4
Prashant Kohli
8 May 24
SC 13G
HIRSCHMAN ORIN
9 Apr 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
3
Robert J DelAversano
8 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.99 mm | 26.99 mm | 26.99 mm | 26.99 mm | 26.99 mm | 26.99 mm |
Cash burn (monthly) | (no burn) | 661.25 k | 1.24 mm | 4.21 mm | 704.33 k | 1.28 mm |
Cash used (since last report) | n/a | 4.87 mm | 9.13 mm | 31.00 mm | 5.19 mm | 9.46 mm |
Cash remaining | n/a | 22.12 mm | 17.86 mm | -4.01 mm | 21.80 mm | 17.53 mm |
Runway (months of cash) | n/a | 33.4 | 14.4 | -1.0 | 31.0 | 13.7 |
Institutional ownership, Q2 2023
1.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 42.68 mm |
Total shares | 148.53 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 67.60 k | $35.00 k |
National Bank of Canada | 18.42 k | $9.66 mm |
Geode Capital Management | 18.35 k | $9.64 mm |
Two Sigma Securities | 15.09 k | $7.92 mm |
Jane Street | 14.22 k | $7.47 mm |
MS Morgan Stanley | 11.30 k | $5.93 mm |
RY Royal Bank Of Canada | 3.51 k | $2.00 mm |
ICA Group Wealth Management | 57.00 | $29.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Prashant Kohli | Stock Options Class A Common Shares | Grant | Acquire A | No | No | 2.96 | 128,770 | 381.16 k | 128,770 |
6 May 24 | Amresh Kumar | Stock Options Class A Common Shares | Grant | Acquire A | No | No | 2.96 | 19,740 | 58.43 k | 19,740 |
6 May 24 | R. Loch Macdonald | Stock Options Class A Common Shares | Grant | Acquire A | No | No | 2.96 | 25,380 | 75.12 k | 25,380 |
6 May 24 | DelAversano Robert J | Stock Options Class A Common Shares | Grant | Acquire A | No | No | 2.96 | 4,500 | 13.32 k | 4,500 |
6 May 24 | Carrie D'Andrea | Stock Options Class A Common Shares | Grant | Acquire A | No | No | 2.96 | 19,740 | 58.43 k | 19,740 |